The CSL (ASX:CSL) share price reached a new 52-week high last week. What's next?

The biotech company share price reached its 52-week high last week.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in biotech giant CSL Limited (ASX: CSL) are in the red this morning, trading at $311 apiece. This comes after the CSL share price nudged past its 52-week highs last week.

After starting last week at $316, CSL shares closed at a high of $318 before reversing course later in the week to finish 1.11% in the red.

This watermark signals an impressive run for the Aussie biotech's share price over the past month or so, having bounced off a low of $286 in early October.

As such, CSL is now trading around its pre-pandemic levels. Let's take a look at what's in store for investors moving forward

What's next for CSL?

Analysts have been cautious on CSL's blood plasma collection volumes for a while. This is important as the company derives a large chunk of its revenue from this route.

When competitor Haemonetics Corporation (NYSE: HAE) recently came in with lower than expected plasma collection results, it subsequently lowered its own plasma-grown guidance for the upcoming year. Given CSL is one of a handful of plasma collectors worldwide, experts use competitors' financials to make estimates.

The team at Morgan Stanley reckon Haemonetics' guidance downgrade might be a headwind for CSL's earnings. Not only that, but experts are also worried about the impact that COVID-19 is still having on plasma donors showing up to clinics.

Even still, Morgan Stanley models a 32% increase for CSL's blood plasma collection volumes this quarter, and this kind of sentiment is also shared by analysts at Macquarie. The latter is bullish about the CSL share price and values it at $338 per share.

Aside from this, CSL's efforts in producing a multi-dose vial (MDV) version of Audenz were recognised by the US Food and Drug Administration (FDA) recently. For reference, Audenz is already approved as a single-dose therapy.

The FDA granted CSL supplemental approval for the MDV that is produced under CSL's Seqirus business. The MDV is labelled as a cell-based influenza vaccine designed to help protect individuals aged 6 months or older in the event of an influenza pandemic.

Under the terms of its partnership with the Biomedical Advanced Research and Development Authority (BARDA), Seqirus will be ready to deliver 150 million influenza vaccine doses to the US to combat an influenza pandemic within six months.

CSL also recently announced that it had secured funding to create an incubator and wet space lab for biotech start-ups, with support from the Victorian government.

The company will team up with Melbourne University and The Walter and Eliza Hall Institute of Medical Research (WEHI) to adopt early-stage biotech companies wanting to advance their discoveries.

As CSL puts it, incubators reduce cost barriers to and other roadblocks to entry for start-ups. Incubators offer a 'one-stop shop' by minimising expenditure on factors that keep small companies priced out of the market.

These developments sit on the horizon for CSL, which could bode in well for its share price judging by the expert commentary and market's reaction.

CSL share price snapshot

The CSL share price has had a difficult period these past 12 months, having gained just 3% in that time. It has rallied over 10% this year to date and has gained over 4% in the past month.

Despite this, it has landed in behind the S&P/ASX 200 Index (ASX: XJO)'s return of around 9% in that time.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on 52-Week Highs

A cloud with a blue arrow pointing upwards through its middle symbolising a rising asx share price
52-Week Highs

7 ASX 200 shares smashing new highs on Tuesday

Here's why these companies are hitting new 52-week highs on Tuesday.

Read more »

Hands reaching high for a trophy with a sunset in the background.
52-Week Highs

6 ASX 200 shares smashing new highs while the market dives today

Do you own any of these lucky ASX 200 stocks?

Read more »

A woman wearing a top of gold coins and large gold hoop earrings and a heavy gold bracelet stands amid a shower of gold coins with her mouth open wide and an excited look on her face.
Gold

14 ASX gold stocks unearthing fresh 52-week highs today

Do you own any of these hot gold miners?

Read more »

An older female ASX investor holds a gangster-style fist pump pose showing off gold rings with dollar signs on them.
52-Week Highs

These 16 ASX 200 shares are hitting new 52-week highs today even as the market sinks

Do you own any of these lucky stocks?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Gold

Why this $9.6 billion ASX 200 gold stock is smashing the market today

This gold miner has hit a 52-week high on Wednesday. What's going on?

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
ETFs

4 ASX ETFs that hit new 52-week highs today

These ETFs provide exposure to the gold price and companies in emerging markets.

Read more »

Two happy scientists analysing test results.
52-Week Highs

3 ASX All Ords health care shares that reached 52-week peaks today

These health care companies finished the week on a positive note.

Read more »

group of friends jump on the beach
52-Week Highs

6 ASX 300 shares that hit new 52-week highs today

Here's why these companies stood out in an otherwise lacklustre day of trading.

Read more »